2018 Press Releases

2018 Press Releases
Home / 2018 Press Releases

2018 Press Releases

Nov-07-2018

Protalix BioTherapeutics Reports 2018 Third Quarter Results and Provides Corporate Update

CARMIEL, Israel, Nov. 07, 2018 (GLOBE NEWSWIRE) -- Protalix BioTherapeutics, Inc. (NYSE American:PLX, TASE:PLX), a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins expressed through its proprietary plant cell-based expression system, ProCellEx®, today announced its financial results for the three months and nine months ended September 30, 2018, and provided a corporate update. “In the third quarter we achieved two important miles... 
Oct-29-2018

Protalix BioTherapeutics to Hold Third Quarter 2018 Financial Results and Corporate Update Conference Call on November 7, 2018

CARMIEL, Israel, Oct. 29, 2018 (GLOBE NEWSWIRE) -- Protalix BioTherapeutics, Inc. (NYSE American:PLX, TASE:PLX), a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins expressed through its proprietary plant cell-based expression system, ProCellEx®, today announced that it will report third quarter 2018 financial results and provide a corporate update on Wednesday, November 7, 2018 at 8:30 am ET. To participate in the conference call... 
Oct-05-2018

Protalix BioTherapeutics Presents Positive Preliminary Data from the BRIDGE Study of pegunigalsidase alfa for the Treatment of Fabry Disease at the 1st Canadian Symposium on Lysosomal Diseases 2018

~Preliminary Results Indicate Significant Improvement in Kidney Function in Patients Switched from agalsidase alfa (Replagal®) to pegunigalsidase alfa (PRX-102)~ A deterioration trend in patients’ kidney function on agalsidase alfa (Replagal®) was reversed to an improvement trend when switched to pegunigalsidase alfa (PRX-102)  Presentation with full data to be held at the 1st Canadian Symposium on Lysosomal Diseases 2018 CARMIEL, Israel, Oct. 05, 2018 (GLOBE NEWSWIRE) -- Protalix BioThe... 
Sep-21-2018

Protalix BioTherapeutics Reports Positive Preliminary Data from the BRIDGE Study of pegunigalsidase alfa for the Treatment of Fabry Disease

Preliminary Results Indicate Improvement in Kidney Function in Patients Switched from agalsidase alfa (Replagal®) to pegunigalsidase alfa (PRX-102) A deterioration trend in patients’ kidney function on agalsidase alfa (Replagal®) was reversed to an improvement trend when switched to pegunigalsidase alfa (PRX-102)  Presentation with full Data to be held at the1st Canadian Symposium on Lysosomal Diseases 2018 CARMIEL, Israel, Sept. 21, 2018 (GLOBE NEWSWIRE) -- Protalix BioTherapeutics, Inc. (... 
Sep-17-2018

Protalix BioTherapeutics to Present Preliminary Data from the BRIDGE Study of pegunigalsidase alfa for the Treatment of Fabry Disease at the 1st Canadian Symposium on Lysosomal Diseases 2018

~Oral Presentation to Include preliminary Kidney Function Data from First 16 Patients Enrolled~ CARMIEL, Israel, Sept. 17, 2018 (GLOBE NEWSWIRE) -- Protalix BioTherapeutics, Inc. (NYSE American:PLX) (TASE:PLX), a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins expressed through its proprietary plant cell-based expression system, ProCellEx®, today announced that the Company will present preliminary data from the BRIDGE study of peg... 
Aug-23-2018

Protalix BioTherapeutics to Present at the 20th Annual Rodman & Renshaw Global Investment Conference

CARMIEL, Israel, Aug. 23, 2018 (GLOBE NEWSWIRE) -- GlobeNewswire /Protalix BioTherapeutics, Inc. (NYSE American:PLX, TASE:PLX), a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins expressed through its proprietary plant cell-based expression system, ProCellEx®, today announced that the Company will present at the 20th Annual Rodman & Renshaw Global Investment Conference, sponsored by H.C. Wainwright & Co., LLC.  The conferenc... 
Aug-13-2018

Protalix BioTherapeutics Appoints David Granot to its Board of Directors

CARMIEL, Israel, Aug. 13, 2018 (GLOBE NEWSWIRE) -- Protalix BioTherapeutics, Inc. (NYSE American: PLX, TASE: PLX), announced today that the Company’s Board of Directors has appointed Mr. David Granot to serve on the Company’s Board of Directors, effective on August 9, 2018.  In addition to Mr. Granot’s appointment as an independent director, he was also appointed to serve on the Company’s Audit Committee. “We are very pleased to have David join our Board of Directors,” commented Shlomo Yana... 
Aug-09-2018

Protalix BioTherapeutics Reports 2018 Second Quarter Results and Provides Corporate Update

CARMIEL, Israel, Aug. 09, 2018 (GLOBE NEWSWIRE) -- Protalix BioTherapeutics, Inc. (NYSE American:PLX, TASE:PLX), a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins expressed through its proprietary plant cell-based expression system, ProCellEx®, today announced its financial results for the six-month period ended June 30, 2018 and provided a corporate update. "This has been a fantastic quarter for the company highlighted by the e... 
Jul-31-2018

Protalix BioTherapeutics to Hold Second Quarter 2018 Financial Results and Corporate Update Conference Call on August 9, 2018

CARMIEL, Israel, July 31, 2018 (GLOBE NEWSWIRE) -- Protalix BioTherapeutics, Inc. (NYSE American:PLX, TASE:PLX), a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins expressed through its proprietary plant cell-based expression system, ProCellEx®, today announced that it will report second quarter 2018 financial results and provide a corporate update on Thursday, August 9, 2018 at 8:30 am ET. To participate in the conference call, ... 
Jul-24-2018

Protalix BioTherapeutics Expands Partnership with Chiesi Farmaceutici to Include Exclusive U.S. Rights for the Development and Commercialization of PRX-102 (pegunigalsidase alfa) for the Treatment of Fabry Disease

Protalix to receive $25 million upfront, an additional up to $20 million in development costs and an additional up to $760 million in potential regulatory and commercial milestone payments for the U.S. rights U.S. partnership includes tiered royalties ranging from 15% to 40% on net sales CARMIEL, Israel, July 24, 2018 (GLOBE NEWSWIRE) -- Protalix BioTherapeutics, Inc. (NYSE American:PLX) (TASE:PLX), a biopharmaceutical company focused on the development and commercialization of recombinant... 
Jun-05-2018

Protalix BioTherapeutics Announces Additional Positive Results from Final Analysis of the Phase II Clinical Trial of OPRX-106 for the Treatment of Ulcerative Colitis

Mucosal Improvement Observed in 61% of the Patients and 33% achieved Mucosal Healing Clinical Responses Observed in 67% of the Patients and Clinical Remission Observed in 28% of the Patients 89% of the Patients Experienced a Reduction in Mayo Score, and 61% of the Patients Experienced a Reduction in Endoscopic Sub Score  No Systemic Absorption Observed CARMIEL, Israel, June 05, 2018 (GLOBE NEWSWIRE) -- Protalix BioTherapeutics, Inc. (NYSE American:PLX) (TASE:PLX), announced today t... 
May-25-2018

Protalix BioTherapeutics Announces Poster Presentation on Baseline Characteristics for Fabry Disease Patients Screened in the Phase III BALANCE Study of Pegunigalsidase Alfa at the 55th ERA-EDTA Congress

Remaining Effective Enzyme in Blood Samples was more than Double for Pegunigalsidase Alfa (PRX-102) Compared to Fabrazyme® as a Result of Higher Inhibition of Neutralizing Antibodies Measured in Fabrazyme CARMIEL, Israel, May 25, 2018 (GLOBE NEWSWIRE) -- GlobeNewswire /Protalix BioTherapeutics, Inc. (NYSE American:PLX) (TASE:PLX), a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins expressed through its proprietary plant cell-based ... 
May-24-2018

Protalix Announces Exchange and Discharge of Remaining 2018 Notes

CARMIEL, Israel, May 24, 2018 (GLOBE NEWSWIRE) -- Protalix BioTherapeutics, Inc. (the “Company”) (NYSE American:PLX) (TASE:PLX) announced today that $3.42 million of the aggregate principal amount of the Company’s outstanding 4.5% Convertible Senior Notes due 2018 (the “Notes”) will be exchanged for 2,613,636 shares of the Company’s common stock and $2.27 million in cash.  Additionally, the Company announced today that it has delivered the necessary funds under the indenture governing the Note... 
May-09-2018

Protalix BioTherapeutics Reports 2018 First Quarter Results and Provides Corporate Update

CARMIEL, Israel, May 09, 2018 (GLOBE NEWSWIRE) -- Protalix BioTherapeutics, Inc. (NYSE American:PLX) (TASE:PLX), a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins expressed through its proprietary plant cell-based expression system, ProCellEx®, today announced its financial results for the three months ended March 31, 2018 and provided a corporate update. "We continue to execute against our upcoming milestones, including the com... 
Apr-26-2018

Protalix BioTherapeutics to Hold First Quarter 2018 Financial Results and Corporate Update Conference Call on May 9, 2018

CARMIEL, Israel, April 26, 2018 (GLOBE NEWSWIRE) -- Protalix BioTherapeutics, Inc. (NYSE American:PLX) (TASE:PLX), a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins expressed through its proprietary plant cell-based expression system, ProCellEx®, today announced that it will report first quarter 2018 financial results and provide a corporate update on Wednesday, May 9, 2018 at 8:30 am ET. To participate in the conference call, p... 
Mar-19-2018

Protalix BioTherapeutics Announces Acceptance of Abstract on OPRX-106 as a Lecture Presentation at the Digestive Diseases Week® 2018

CARMIEL, Israel, March 19, 2018 (GLOBE NEWSWIRE) -- Protalix BioTherapeutics, Inc. (NYSE American:PLX) (TASE:PLX), a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins expressed through its proprietary plant cell-based expression system, ProCellEx®, today announced that an abstract detailing the results from the Company’s phase IIa clinical trial of OPRX-106 for the treatment of ulcerative colitis results has been accepted for a lectu... 
Mar-15-2018

Protalix BioTherapeutics to Present at BioCentury’s 25th Annual Future Leaders in the Biotech Industry Conference

CARMIEL, Israel, March 15, 2018 (GLOBE NEWSWIRE) -- Protalix BioTherapeutics, Inc. (NYSE American:PLX) (TASE:PLX), a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins expressed through its proprietary plant cell-based expression system, ProCellEx®, today announced that Moshe Manor, the Company's President and Chief Executive Officer, will present a corporate overview at BioCentury’s 25th Annual Future Leaders in the Biotech Industry ... 
Mar-13-2018

Protalix BioTherapeutics Announces Positive Results from Phase II Clinical Trial of OPRX-106 for the Treatment of Ulcerative Colitis

Clinical Responses Observed in 67% of Patients and Clinical Remission Observed in 28% of Patients No Anti-Drug Antibodies Detected CARMIEL, Israel, March 13, 2018 (GLOBE NEWSWIRE) -- Protalix BioTherapeutics, Inc. (NYSE American:PLX) (TASE:PLX), announced today, positive results from the Company’s phase II clinical trial of OPRX-106 for the treatment of ulcerative colitis.  OPRX-106 is a plant cell-expressed recombinant human tumor necrosis factor receptor II fused to an IgG1 Fc domain (TN... 
Mar-06-2018

Protalix BioTherapeutics Reports 2017 Full Year Results and Provides Corporate Update

Enrollment in all Fabry Trials is ongoing in over Forty Active Sites Current Cash is Projected to Fund the Company through Clinical Trial Read-Outs and into 2020 CARMIEL, Israel, March 06, 2018 (GLOBE NEWSWIRE) -- Protalix BioTherapeutics, Inc. (NYSE American:PLX) (TASE:PLX), a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins expressed through its proprietary plant cell-based expression system, ProCellEx®, today announce... 
Feb-26-2018

Protalix BioTherapeutics to Hold Full-Year 2017 Financial Results and Corporate Update Conference Call on March 6, 2018

CARMIEL, Israel, Feb. 26, 2018 (GLOBE NEWSWIRE) -- Protalix BioTherapeutics, Inc. (NYSE American:PLX) (TASE:PLX), a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins expressed through its proprietary plant cell-based expression system, ProCellEx®, today announced that it will report full-year 2017 financial results and provide a corporate update on Tuesday, March 6, 2018 at 8:30 am ET. To participate in the conference call, please... 
Feb-15-2018

Protalix BioTherapeutics Announces Final Dosing of Last Patient in Phase II Clinical Trial of OPRX-106 in Patients with Ulcerative Colitis

CARMIEL, Israel, Feb. 15, 2018 (GLOBE NEWSWIRE) -- Protalix BioTherapeutics, Inc. (NYSE American:PLX) (TASE:PLX), announced today the final dosing of the last patient in the Company’s phase II clinical trial evaluating OPRX-106, the Company’s oral antiTNF product candidate, in patients with ulcerative colitis (UC).  OPRX-106 is the Company’s proprietary plant cell-expressed recombinant human tumor necrosis factor receptor II fused to an IgG1 Fc domain (TNFRII-Fc).  The Company expects to repor... 
Jan-31-2018

Protalix BioTherapeutics’ pegunigalsidase alfa Receives Fast Track Designation from the U.S. Food and Drug Administration

Fast Track designation highlights high unmet medical need in the treatment of Fabry disease CARMIEL, Israel, Jan. 31, 2018 (GLOBE NEWSWIRE) -- Protalix BioTherapeutics, Inc. (NYSE American:PLX) (TASE:PLX), announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to pegunigalsidase alfa, or PRX-102, the Company’s plant cell-expressed recombinant, pegylated, cross-linked α-galactosidase-A candidate for the treatment of Fabry disease.  The FDA’s Fast Track ... 
Jan-29-2018

Protalix BioTherapeutics to Participate in the 14th Annual WORLDSymposium™ 2018

Data to be presented in an oral presentation and two poster presentations CARMIEL, Israel, Jan. 29, 2018 (GLOBE NEWSWIRE) -- Protalix BioTherapeutics, Inc. (NYSE MKT:PLX) (TASE:PLX), announced today that the Company will participate in the 14th Annual WORLDSymposium™ 2018 taking place February 5 – 8, 2018 at the Manchester Grand Hyatt, San Diego, CA. Presentations Details: “Enhanced pharmacokinetics profile of pegunigalsidase alfa (PRX-102) supports once-monthly 2mg/kg dosing for the ... 
Jan-02-2018

Protalix BioTherapeutics Reports Positive Interim Data from Phase II Clinical Trial of OPRX-106 in Patients with Ulcerative Colitis

CARMIEL, Israel, Jan. 02, 2018 (GLOBE NEWSWIRE) -- Protalix BioTherapeutics, Inc. (NYSE American:PLX) (TASE:PLX), announced today interim data from the first 14 patients that completed, to date, the Company’s phase II clinical trial of OPRX-106 (oral anti-TNF) in patients with ulcerative colitis. The phase II clinical trial is a randomized, open label, 2-arm study of OPRX-106 in patients with active mild to moderate ulcerative colitis.  A total of 24 patients were enrolled and randomized to...